TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 6B 12B 18B Q3 '21: 16.2B Q4 '21: 15.9B Q1 '22: 15.6B Q2 '22: 15.4B Q3 '22: 15.1B Q4 '22: 14.9B Q1 '23: 14.9B Q2 '23: 15B Q3 '23: 15.3B Q4 '23: 15.8B Q1 '24: 16B Q2 '24: 16.3B Q3 '24: 16.8B Q4 '24: 16.5B Q1 '25: 16.6B Q2 '25: 16.6B Q3 '25: 16.8B Q4 '25: 17.3B Q1 '26: 17.3B Q2 '26: 17.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 3.5B 7B 10.5B Q3 '21: 7.6B Q4 '21: 7.6B Q1 '22: 7.5B Q2 '22: 7.4B Q3 '22: 7.3B Q4 '22: 7B Q1 '23: 6.8B Q2 '23: 6.8B Q3 '23: 7B Q4 '23: 7.6B Q1 '24: 7.8B Q2 '24: 8.1B Q3 '24: 8.4B Q4 '24: 8.1B Q1 '25: 8.2B Q2 '25: 8.2B Q3 '25: 8.4B Q4 '25: 8.9B Q1 '26: 9B Q2 '26: 9.1B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income TTM

-2.4B -1.6B -800M 0 800M 1.6B 2.4B Q3 '21: 2B Q4 '21: 1.7B Q1 '22: 570M Q2 '22: -961M Q3 '22: -1.2B Q4 '22: -2.2B Q1 '23: -1.5B Q2 '23: -1.2B Q3 '23: -1.3B Q4 '23: 433M Q1 '24: 228M Q2 '24: 877M Q3 '24: 482M Q4 '24: -303M Q1 '25: 434M Q2 '25: 894M Q3 '25: 1.8B Q4 '25: 2.2B Q1 '26: 2.3B Q2 '26: 1.6B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q3 '20: -4B Q4 '20: -4B Q1 '21: -4B Q2 '21: -3.9B Q3 '21: 726M Q4 '22: -2.4B Q1 '23: -1.7B Q2 '23: -2.3B Q3 '23: -2.3B Q4 '23: -559M Q1 '24: -478M Q2 '24: -452M Q3 '24: -958M Q4 '24: -1.6B Q1 '25: -1.3B Q2 '25: -158M Q3 '25: 712M Q4 '25: 1.4B Q1 '26: 1.6B Q2 '26: 706M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 3B 6B 9B Q3 '21: 8.6B Q4 '21: 8.3B Q1 '22: 8.1B Q2 '22: 8.1B Q3 '22: 7.9B Q4 '22: 8B Q1 '23: 8.1B Q2 '23: 8.2B Q3 '23: 8.3B Q4 '23: 8.2B Q1 '24: 8.2B Q2 '24: 8.2B Q3 '24: 8.4B Q4 '24: 8.5B Q1 '25: 8.4B Q2 '25: 8.4B Q3 '25: 8.4B Q4 '25: 8.3B Q1 '26: 8.3B Q2 '26: 8.2B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

0 700M 1.4B 2.1B Q3 '21: 673M Q4 '21: 798M Q1 '22: 1.2B Q2 '22: 1.1B Q3 '22: 1.1B Q4 '22: 1.6B Q1 '23: 1.5B Q2 '23: 1.7B Q3 '23: 1.2B Q4 '23: 1.4B Q1 '24: 1.4B Q2 '24: 1.2B Q3 '24: 1.9B Q4 '24: 1.2B Q1 '25: 1.3B Q2 '25: 1.4B Q3 '25: 1.1B Q4 '25: 1.6B Q1 '26: 1.7B Q2 '26: 1.9B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

0 500M 1B 1.5B Q3 '21: 88M Q4 '21: 236M Q1 '22: 585M Q2 '22: 476M Q3 '22: 514M Q4 '22: 1B Q1 '23: 964M Q2 '23: 1.2B Q3 '23: 608M Q4 '23: 842M Q1 '24: 878M Q2 '24: 679M Q3 '24: 1.4B Q4 '24: 749M Q1 '25: 765M Q2 '25: 890M Q3 '25: 578M Q4 '25: 1.1B Q1 '26: 1.2B Q2 '26: 1.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q1 '20: 1.1B Q2 '20: 1.1B Q3 '20: 1.1B Q1 '21: 1.1B Q2 '21: 1.1B Q3 '21: 1.1B Q1 '22: 1.1B Q2 '22: 1.1B Q3 '22: 1.1B Q1 '23: 1.1B Q2 '23: 1.1B Q3 '23: 1.1B Q1 '24: 1.1B Q2 '24: 1.1B Q3 '24: 1.1B Q1 '25: 1.2B Q2 '25: 1.2B Q3 '25: 1.2B Q1 '26: 1.2B Q2 '26: 1.2B Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: -3.68 Q4 '20: -3.64 Q1 '21: -3.63 Q2 '21: -3.57 Q3 '21: 0.66 Q4 '22: -2.19 Q1 '23: -1.53 Q2 '23: -2.10 Q3 '23: -2.09 Q4 '23: -0.50 Q1 '24: -0.42 Q2 '24: -0.39 Q3 '24: -0.84 Q4 '24: -1.45 Q1 '25: -1.15 Q2 '25: -0.16 Q3 '25: 0.60 Q4 '25: 1.20 Q1 '26: 1.33 Q2 '26: 0.60 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.